Introduction
General considerations Certain considerations apply to all forms of crystal deposition, in particular the factors determining whether or not crystallisation occurs. This largely concerns the activity products of the ions involved, although the presence of nucleating agents or inhibitory agents, or both, must be considered. Solubilisation processes may also be important.
The purpose of this presentation is twofold: (a) to review current knowledge of the metabolism of inorganic pyrophrosphate and (b) to describe some of the mechanisms that may be involved in the production of CPDD crystals, both in vitro and in vivo. Table 1 summarises the factors to be considered in relation to the deposition of CPPD crystals and the association of chondrocalcinosis with endocrine and metabolic diseases. The reasons for these clinical associations are not always clear but they indicate that a variety of metabolic disturbances may lead to deposition of pyrophosphate crystals.
CPPD deposition is also more common in the presence of other joint disease, including osteoarthropathy,5 neuropathic (Charcot) joint disease,7 and gout.5 In such cases the destructive changes that occur may induce alterations of pyrophosphate metabolism within the joint leading to increased crystal formation.
The increased incidence of CPPD deposition with aging may also be related to the changes that occur in cartilage with age.
A familial form of chondrocalcinosis was described by Zitnan and Sit'aj in 1958," although at that time it was not known that CPPD was the calcium salt responsible. Subsequently other familial forms have been described.'0"'-The existence of these inherited forms allow a comparison with classic gout where specific enzyme defects have occasionally been identified--for example, in the Lesch-Nyhan syndrome. ' 
